Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR–ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction

Abstract

BCR–ABL1 point mutations are the most common cause of resistance in patients with chronic myeloid leukemia (CML) who fail or lose response to tyrosine kinase inhibitors. We have developed a rapid method to screen BCR–ABL1 mutations by high resolution melting (HRM). We designed a strategy based on amplification refractory mutational system-quantitative polymerase chain reaction (ARMS-qPCR) to identify and quantify several clinically relevant mutations. From 856 patients with CML studied during 2 years in our laboratory, we selected 32 who showed persistent levels of BCR–ABL1 transcripts (>0.1%) in at least two consecutive studies. Using our strategy, we identified mutations in 11/32 cases (34.4%), while only two of them (6.2%) were detectable by sequencing. Furthermore, we were able to estimate the timing and dynamics of mutated clones, evaluating retrospective samples from the same patient. In cases with lack or loss of molecular response this analysis might be useful for designing early therapeutic strategies.

Keywords::

• CML
• HRM
• ARMS
• screening
• mutations

Acknowledgements

This study was supported by grants from Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and Agencia Nacional de Producción Científica y Tecnológica (ANPCyT).

Potential conflict of interest

Disclosure provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.